The reason why the PA catheter trials have been so inconclusive is because there have been such varying goals or protocols associated with their use.
The Fluid and Catheter Treatment Trial (FACTT) trial showed that liberal volume administration (which could include RBC transfusion) was associated with poor outcomes in hemodynamically stable ALI patients [ 16], but the primary analysis did not examine the specific association between transfusion and clinical outcomes.
Using data obtained in the Fluid and Catheter Treatment Trial (FACTT), a randomized controlled trial in critically ill patients with ALI [ 20, 21], we investigated whether genetic variation in single nucleotide polymorphisms (SNPs) in FAS and related genes is associated with AKI.
ARDS: Acute respiratory distress syndrome; ARDSnet: Acute respiratory distress syndrome clinical trials network; FACTT: Fluid and catheter treatment trial; PAC: Pulmonary artery catheter.
In the Acute Respiratory Distress Syndrome Clinical Trials Network (ARDSnet) Fluid and Catheter Treatment Trial (FACTT), a multi-center, nationwide, elaborately designed trial sponsored by the National Institutes of Health's National Heart , Lung and Blood Institute the effect of placing a PAC in patients with acute respiratory distress syndrome (ARDS) was studied [ 7].
Fluid and Catheter Treatment Trial.
In the Fluid and Catheter Treatment Trial (FACTT), the conservative fluid strategy was associated with a trend towards a reduced requirement for renal replacement therapy [59].
The ARDS Clinical Trials Network Fluid and Catheter Treatment Trial (FACTT) addressed fluid management and central monitoring of patients with acute respiratory distress syndrome/acute lung injury (ARDS/ALI).
A restrictive, post resuscitation, fluid balance strategy for patients with Acute Respiratory Distress Syndrome (ARDS) has been suggested by the fluid and catheter treatment trial (FACTT) study in 2006.
In another study in the low tidal volume ventilation era, Bull et al. demonstrated that pulmonary vascular dysfunction, which they defined as elevated transpulmonary gradient and pulmonary vascular resistance index measured by PAC in patients enrolled in the NIH ARDS Network Fluid and Catheter Treatment Trial [28], was an independent risk factor for 60-day mortality [29].
